Qiagen, Inovio to partner on cervical dysplasia test

By LabPulse.com staff writers

February 24, 2021 -- Qiagen and Inovio have announced they will develop a next-generation sequencing (NGS) test for HPV-linked advanced cervical dysplasia that can be used on Illumina's NextSeq 550Dx platform.

The liquid biopsy-based test aims to guide patient selection and offer a noninvasive alternative to having cervical lesions removed. It will be a companion test for Inovio's VGX-3100. Qiagen's expertise in bioinformatics will boost the predictive power of Inovio's preliminary biomarker signature.

Copyright © 2021 LabPulse.com

To read this and get access to all of the exclusive content on LabPulse.com, create a free account or sign in now.

Member Sign In:
MemberID or email address:  
Do you have a LabPulse.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?